tbuckley/cabot-search huggingface dataset:
The role of alpha-fetoprotein in maintaining the growth of human hepatoma cells
Authors: M. Li, S. Zhou, X. Liu, G. Li
Journal: Journal of Clinical Oncology (2006)

14081 Background: This study was to explored the functional mechanism of alpha-fetoprotein (AFP) in maintaining the proliferation of human hepatoma cells line Bel 7402 and the immunsuppression of lymphocyte Jurkat cells. Methods: Western blot was used to detecting the expression of some apoptosis-related gene, fluorescence labeled AFP and confocal microscopy scanning for receptor binding assay in the membrane in Jurkat cells. Results: It showed that AFP could enhance the expression of survivin and c-ras, but restrain caspase-3 express in Bel 7402 cells by Western blotting analysis. It also showed that AFP could bind to the membrane of Jurkat cells by confocal microscopy scanning, and when treated Jurkat with AFP, it indicated that AFP could repress the expression of survivin and Livin and elevated the activity of caspase-3 in the cells; Co-cultured Bel 7402 cells with Jurkat cells, the expression of tumor necrosis related-apoptosis induced ligand (TRAIL) in Jurkt cells was inhibited, when pretreatment with monoclonal antibody of AFP (Anti-AFP), the restrained effect of TRAIL express and the activity of caspase-3 was elevated in Jurkat cells was removed. It also indicated that Anti-AFP had an ability to block these functions of AFP. Conclusions: AFP has a capability to promote the growth and escape from immune surveillance of human hepatoma cells through enhancing the expression of ras and survivin gene in Bel 7402 cells, suppressing TRAIL, survivin and Livin expressed and upregulated activity of caspase-3 in Jurkat cells. No significant financial relationships to disclose.
セツキシマブはIGROV-1ヒト卵巣癌細胞株におけるP-糖タンパク質の機能を抑制する
Authors: Chu Celine, Jovelet Cecile, Noeel-Hudson Marie-Sophie, Benard Jean, Farinotti Robert, Bonhomme-Faivre Laurence
Journal: Annals of Oncology (2011)
Abstract 2753: The germline TP53 p.R337H mutation: a putative selective advantage
Authors: Kelvin César Andrade, Ana Carolina Leite, Amanda Nobrega, Sharon Savage, Maria Isabel Achatz
Journal: Cancer Research (2015)

Abstract Li-Fraumeni syndrome is a hereditary cancer predisposition disorder related to germline TP53 mutations. Although it is considered to be a rare condition worldwide, a high occurrence of a founder mutation, the p.R337H TP53, is present in 0.3% of Southern Brazilian population. In a subgroup of p.R337H carriers, specific characteristics associated with late aging were clinically observed, such as a lower frequency of metabolic alterations and diseases typical of aging. However, despite of these particular features no study has clinically characterized these individuals until the moment. Therefore, our aim was to evaluate clinical features of p.R337H carriers and compare them with a control group. We used a clinical form composed by information on physical characteristics, personal habits, clinical history of diseases and physical activity throughout life. After IRB approval, we applied it in 48 p.R337H carriers (mean age: 46,8; range: 16-100) and in 38 carrier's relatives who were mutation-negative, as controls, (mean age 52,7; range: 18-90). Fisher's exact test was performed for statistical analysis. Regarding personal characteristics and habits, no difference was found between groups neither among p.R337H asymptomatic and affected carriers. However, some diseases discrepancies were found: In individuals older than 55 years of age, prevalence of osteoporosis was significantly lower in the p.R337H group when compared to controls (12% vs 59%; p&amp;lt;0,05). Anemia was also less frequent in p.R337H carriers (0% vs 13%; p&amp;lt;0,05) when all ages are considered. Although non-statistically significant, lower frequencies of neurodegenerative disorders, gastritis and thyroid dysfunction were also observed in the p.R337H group. These findings provide further information about a better overall health in p.R337H carriers, suggesting a possible selective advantage. This could be a plausible explanation for why this deleterious mutation has persisted throughout successive generations. More detailed clinical characterization studies are under way as well as molecular approaches looking for interactions between the p.R337H mutation and cellular senescence mechanisms. Citation Format: Kelvin César Andrade, Ana Carolina Leite, Amanda Nobrega, Sharon Savage, Maria Isabel Achatz. The germline TP53 p.R337H mutation: a putative selective advantage. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2753. doi:10.1158/1538-7445.AM2015-2753
Abstract 15816: Repetitive Ct-Examinations Over a 5 Year Period Show Low Individual Change in Percentile of Coronary Artery Calcification Score in Subjects With Prevalent Coronary Calcification - The Population Based Heinz Nixdorf Recall Study
Authors: Amir A Mahabadi, Nils Lehmann, Stefan Mohlenkamp, Hagen Kalsch, Marcus Bauer, Susanne Moebus, Karl-Heinz Jockel, Raimund Erbel
Journal: Circulation (2013)

Background: Progression of coronary artery calcification (CAC) is associated with increased risk for cardiac events. While the CAC-score increases with age, intra-individual changes in CAC percenti...
원저 / Dimethylnitrosamine에 의한 백서의 간섬유화 과정에서 Pentoxifylline과 Ciprofloxacin의 영향
Authors: 서강석(Kang Suek Suh), 이창훈(Chang Hun Lee), 설미영(Mee Young Sol), 이선경(Sun Kyung Lee)
Journal: Clinical and Molecular Hepatology (2001)

Background/Aims: Hepatic fibrosis is known to be a predisposing condition of cirrhosis for which there is no proven effective therapy. The aim of this study was to investigate the effect of pentoxifylline and ciprofloxacin on biochemical and histological features of rat hepatic fibrosis induced by dimethylnitrosamine (DMN). Methods: Seventy male Sprague-Dawley rats were divided into four groups including control (n = 10), DMN (n = 20), DMN plus pentoxifylline (n = 20) and DMN plus ciprofloxacin (n = 20). The rats were injected intraperitoneally with normal saline in the control group and the aforementioned chemicals in the study groups three times a week for 3 weeks. Two rats of the control group, and fives of each study group were sacrificed weekly after the beginning of experiment. From sacrified rats the following parameters of hepatic fibrosis were determined: AST, ALT, cytokines IL-1β, TNF-α and INF-γ, and histological features of hepatic tissue. Result: Rat weight, serological and histological findings were distinctively improved in two treated groups compared with untreated DMN group(p<0.05), The antifibrogenic activity between treated groups was rather better in the group treated with pentoxifylline than in the group treated with ciprofloxacin. During the first and second weeks after experiment the distribution of hepatic stellate cells in treated groups was limited, whereas DMN group showed their diffuse distribution. At the third week DMN group displayed micronodular cirrhosis, but treated groups showed only mild centrilobular fibrotic areas without developing cirrhosis. Conclusion: Our results indicate that pentoxifylline and cirprofloxacin may be protective against DMN induced rat hepatic fibrogenesis, while accompanying the inhibition of hepatic stellate cells during the early stage of hepatic fibrogenesis.(Korean J Hepatol 2001;7:34-46)
Elevated plasma levels of vascular permeability factors in C1 inhibitor‐deficient hereditary angioedema
Authors: S. Loffredo, M. Bova, C. Suffritti, F. Borriello, A. Zanichelli, A. Petraroli, G. Varricchi, M. Triggiani, M. Cicardi, G. Marone
Journal: Allergy (2016)

Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is a rare inherited genetic disease characterized by recurrent swelling episodes of the skin, gastrointestinal tract, and upper airways. Angioedema attacks result from increased vascular permeability due to the release of bradykinin from high molecular weight kininogen. Currently, there are no biomarkers predicting the frequency of angioedema attacks. Vascular permeability is modulated by several factors, including vascular endothelial growth factors (VEGFs) and angiopoietins (Angs). As increased circulating levels of VEGFs and Angs have been observed in diseases associated with higher vascular permeability (e.g., systemic capillary leak syndrome and sepsis), we sought to analyze plasma concentrations of VEGFs and Angs in patients with C1-INH-HAE.Sixty-eight healthy controls and 128 patients with C1-INH-HAE were studied. Concentrations of angiogenic (VEGF-A, Ang1, Ang2), anti-angiogenic (VEGF-A165b ) and lymphangiogenic (VEGF-C) factors were evaluated by ELISA. C1-INH functional activity was assessed by EIA.Plasma concentrations of VEGF-A, VEGF-C, Ang1, and Ang2 were higher in patients with C1-INH-HAE in remission than in healthy controls. Concentration of VEGF-A was further increased in patients with lower C1-INH functional activity. Patients with C1-INH-HAE experiencing more than 12 angioedema attacks per year were characterized by higher plasma levels of VEGF-A, VEGF-C, and Ang2 compared with the other patients.We hypothesize that VEGFs and Angs induce a state of 'vascular preconditioning' that may predispose to angioedema attacks. In addition, the identification of increased plasma levels of VEGFs and Angs in patients with C1-INH-HAE may prompt the investigation of VEGFs and Angs as biomarkers of C1-INH-HAE severity.
A retrospective and prospective study of response to aromatase inhibitors and TAM in HER2-overexpressed postmenopausal breast cancer patients
Authors: J. Zhang, Y. Liu
Journal: Journal of Clinical Oncology (2008)

11577 Background: Observe response to aromatase inhibitors and TAM in HER2-overexpressed postmenopausal breast cancer patients. Methods: Collect 501 patients given tamoxifen (TAM 2.5mg Qd, po) and 232 patients given aromatase inhibitors (letrozole 10 mg Bid, po) from 2002.7 to 2005.3. Select randomly 300 cases from 2004.8 to 2005.8. Randomly give tamoxifen or aromatase inhibitors. All patients are postmenopausal and ER-positive. Results: Retrospective study results: 1. In TAM group, 3-year DFS of HER2- overexpressed ones is lower than that of HER2-negative ones. (1) No difference existed between HER2-overexpressed and HER2-negative ones in node-negative group. But difference existed in node-positive group (p=0.037). (2) In HER2-overexpressed group, ER+/PR+ ones is higher than ER+/PR- ones. 2. In AIs group, no difference between HER2-overexpressed and HER2-negative ones. (1) Also no difference in node- positive or node-negative group. (2) In HER2-overexpressed group, ER+/PR+ is higher than that of ER+/PR-. Prospective study results: 3-year DFS of patients treated with AIs is higher than that of TAM. (1) In HER2- overexpressed group, AIs is higher than TAM (p=0.024); but no difference in HER2 negative group.(2) In node-positive group, AIs vs TAM is 89.7% vs 88.5% (p=0.04); no difference in node-negative group. (3) In ER+/PR-group, AIs is higher than that of TAM. And also in ER+/PR- group. (4) In node-positive patients with HER2-overexpression, 3-year DFS of AIs is higher than that of TAM. (5) Safety: hot flushed, vaginal bleeding and thromboembolic of AIs group is much lower, but muscle pain and bone fracture is higher than TAM group (p<0.05). AIs couldn’t increase risk of endometrial cancer and thromboembolic. Conclusions: Retrospective study shows HER2-overexpressed patients will resistant to TAM therapy; but HER2 expression won’t influence postmenopausal node-negative ones. Prospective study suggested HER2-overexpressed patients are sensitive to aromatase inhibitors and won’t be influenced by node status; AIs is more effective for postmenopausal patients with ER-positive or HER2- overexpressed ones; AIs has good tolerance and safety. No significant financial relationships to disclose.
Morphology of Simian Foamy Viruses, &lt;italic&gt;With Particular Reference to Virus Isolated From Spontaneous Tumor of o Rhesus Monkey&lt;/italic&gt;
Authors: Harish C. Chopra, John J. Hooks, M. J. Walling, Clarence J. Gibbs, Jr.
Journal: JNCI Journal of the National Cancer Institute (1972)

The morphogenesis of 7 serotypes of foamy viruses, 5 isolated from monkeys and 2 from chimpanzees, was investigated by electron microscopy. Prototype simian viruses propagated in cultures of human embryonic kidney cells and green monkey kidney (vero) cells induced multinucleated giant cells which subsequently developed vacuoles and a foamy appearance. By electron microscopy, foamy virus types 1–7 showed similar modes of development and general morphology. The representative type strains differed slightly in their size and surface projections. In each instance, however, virions consisted of an outer envelope with projections and a ring-shaped inner component. The internal component appeared in the cytoplasm and by budding process became enveloped by the cell membrane. In contrast, the monkey tumor virus lacked surface projections and consisted of an inner dense nucleoid. Also, foamy virus types 1–7 were antigenically distinct from the virus derived from the monkey kidney, since by neutralization and immunofluorescence tests they did not cross-react with each other. The striking morphologic resemblance of the foamy viruses to the known oncogenic viruses and the recent findings of an RNA-dependent DNA polymerase in some types tested warrant further studies to determine possible oncogenic capabilities.
Exhaled nitric oxide reference values in healthy Tunisian adults
Authors: Sonia Rouatbi, Mohamed Ali Chouchène, Helmi Ben Saad
Journal: European Respiratory Journal (2013)

Nitric oxide (NO) can be detected in human exhaled air, and its endogenous production is increased in patients with asthma. The objectives of this study were: to determine, in healthy Tunisian adults aged 20 to 60 years, the factors influencing the exhaled fraction of NO (FeNO) values and to establish their reference equation or value table.  Methods: It was a cross-sectional analytical study. Healthy Tunisian adults in the region of Sousse, aged 20 to 60 years were recruited. First subjects have responded to a questionnaire, then exhaled NO levels were measured by an online method with electrochemical analyzer. The anthropometric data and pulmonary function data were collected. Simples and a multiple linear regressions were determined. The upper limit of normal (ULN) was defined. Results: 257 subjects were retained. In the total sample, gender did not significantly affect the FeNO values. For practical and routine interpretation of FeNO, two methods were proposed: use of reference equation or use of normal values. For a practical interest, and as gender doesn’t significantly affect the FeNO value, we recommend the use of the total sample reference equation when calculating a predicted FeNO value: FeNO (ppb) = exponential (3.466936 – 0.560725 x Height (m)). After the predicted FeNO value for a given male was computed from this equation, the ULN for the male could be obtained by adding 0.5992724 ppb.  Conclusion: We have established reliable and available reference equation and normal values to interpret the results of FeNO in healthy Tunisian adults. Our FeNO reference equation enriches the world bank of reference equations, in which physician could choose according to their regional localization or patient ethnic.
Impact of statins and survival outcomes in patients with metastatic renal cell carcinoma.
Authors: Rana R. McKay, Xun Lin, Laurence K. Albiges, Andre Poisl Fay, Marina Dusevic Kaymakcalan, Suzanne S Mickey, Paiman Peter Ghoroghchian, Rupal Satish Bhatt, Ronit Simantov, Toni K. Choueiri, Daniel Yick Chin Heng
Journal: Journal of Clinical Oncology (2015)

435 Background: A growing body of evidence has demonstrated the antineoplastic activity of statins. The objective of this study was to investigate the impact of statin use on survival in patients with metastatic renal cell carcinoma (mRCC) treated in the modern therapy era. Methods: We conducted a pooled analysis of mRCC patients treated on phase II and III clinical trials. Statistical analyses were performed using Cox regression adjusted for age, sex, race, histology, prior therapy, body-mass index, and other known prognostic factors and the Kaplan-Meier method. Results: We identified 4,736 patients treated with sunitinib (n=1,059), sorafenib (n=772), axitinib (n=896), temsirolimus (n=457), temsirolimus + interferon-alpha (n=208), bevacizumab + temsirolimus (n=393), bevacizumab + interferon-alpha (n=391), or interferon-alpha (n=560), of whom 511 were statin users. Overall, statin users demonstrated a statistically significant improvement in overall survival (OS) but not progression-free survival (PFS) compared to non-users (OS: 25.6 versus 18.9 months; p=0.015; adjusted hazard ratio [aHR] 0.787; 95% CI, 0.648-0.955; PFS: 7.9 versus 6.9 months; p=0.823, aHR 1.018; 95% CI, 0.867-1.196). When stratified by therapy type, a benefit in OS was demonstrated in statin users compared to non-users in individuals receiving therapy targeting vascular endothelial growth factor (28.4 versus 22.2 months, p=0.023; aHR 0.749; 95% CI, 0.584-0.961) or mammalian target of rapamycin (18.6 versus 14.0; p=0.035; aHR 0.657; 95% CI, 0.445-0.972), but not in those receiving interferon-alpha (15.6 versus 14.8 months; p=0.410; aHR 1.292; 95% CI 0.703-2.275). Adverse events were similar between statin users and non-users. Conclusions: In the largest RCC analysis to date, we demonstrate that statin use improved survival outcomes in patients with mRCC treated in the targeted therapy era. Statins could represents a potential adjunct therapeutic option for patients with metastatic RCC; however, this hypothesis needs to be corroborated with preclinical work exploring the mechanisms underlying their anti-cancer effects and well-designed clinical trials investigating the clinical benefits of adding statins to modern therapies.
Strain A Mouse Pulmonary Tumor Test Results for Chemicals Previously Tested in the National Cancer Institute Carcinogenicity Tests
Authors: R R Maronpot, M B Shimkin, H P Witschi, L H Smith, J M Cline
Journal: JNCI Journal of the National Cancer Institute (1986)

Sixty-five chemicals were coded and examined for their ability to induce lung tumors in strain A/St (laboratory A) or strain A/J (laboratory B) mice. Thirty-five chemicals were tested in laboratory A only, 6 in laboratory B only, and 24 in both laboratories. Two-year carcinogenicity test results as well as genotoxicity test data are available for most of these chemicals. There was poor interlaboratory agreement in strain A test results for the 24 chemicals tested in both laboratories. In addition, there was poor agreement between strain A test results trom either laboratory and 2-year carcinogenicity test results or genotoxicity results. Possible explanations for these findings include selection of a large number of aromatic amines in the group of chemicals submitted for strain A testing, differences in strain A testing protocols and in statistical analysis of results from the two laboratories, low sensitivity of the strain A/St mice used in this particular study, and general problems inherent in comparing any relatively short-term animal tumor model with 2-year carcinogenicity tests. Since there is no absolute reference for carcinogenicity, no one test system is better than another. Carcinogenicity test data are relevant only to the test model employed.
Analysis of patients diagnosed as rectal carcinoma treated with neoadjuvant chemoradiotherapy and radiotherapy alone
Authors: B. Askaroglu, M. H. Akboru, S. T. Dincer, T. Hancilar, A. Yoney, L. Isikli, M. Unsal
Journal: Journal of Clinical Oncology (2007)

14582 Background: Surgery is the standart of the treatment in rectal carcinoma with the help of radiotherapy and chemotherapy applied before or after the operation. Neoadjuvant usage of radiochemotherapy had promising results in randomised trials and in meta-analysis. Methods: We evaluated rectal cancer patients admitted to our center between January 1999-December 2004 retrospectively. Sixty-eight patients were documented. Seventy-five percent of them were male. All of them had adenocarcinoma in histology (19.1% and 5.9% had mucinous and signet ring components respectively). Most of the patients were in Stage II (83.8%). Median 50.4 Gy (45–72 Gy) radiotherapy was delivered in 1.8 Gy fraction dose. Chemoradiotherapy was applied in 86.8% of cases (5-fluorouracil in 35.3% and raltitrexed in 51.5% of them). In operated patients 4 cycle bolus 5-fluorouracil and leucovorin were delivered as adjuvant treatment. Results: Median follow up was 23 months (1–70 months). Downstaging was seen in 54.4 % of cases. In ten (14.7%) patients total response were detected. Six of them (8.8%) were clinically total responders and were not operated. Downstaging was recorded better in 5-fluorouracil group (66.7% versus 37.1%) and it was statistically significant (p&lt; 0.05). Local recurrence and metastasis were seen in 16.2% and 17.6% of the cases respectively. Highest local recurrence rate was seen in T4 stage (42.9%) and highest rate of metastasis was seen in poorly differentiated histology. Regarding all patients; disease free survival and overall survival in three years were 77.7% and 81.4% respectively. There were no statistically significant difference between subgroups of different chemotherapy schedules. Grade I, II and III gastrointestinal system toxicities were seen 16.7%, 48.5% and 15.2% respectively. They were 70.6%, 11.8% when considering Grade I and II hematological toxicities. Conclusions: Neoadjuvant chemoradiotherapy regimens provide downstaging, preserve anal sphincter functions and make easier the surgical approach. In our study 5- fluorouracil seems to be better than raltitrexed but further larger scale randomised trials must be done with different chemotherapeutic agents to state the advantages of neodjuvant chemoradiotherapy in rectal cancer. No significant financial relationships to disclose.
Immunocytochemical determination of the estrogen-regulated proteins Mr 24, 000, Mr 52, 000 and DF3 breast cancer associated antigen: Clinical value in advanced breast cancer and correlation with estrogen receptor
Authors: L. Damstrup, J. Andersen, D.W. Kufe, D.F. Hayes, H. Skovgaard Poulsen
Journal: Annals of Oncology (1992)